Critics argue that the Controlled Substance Act effectively turned the United States government into enforcers for the pharmaceutical industry. The legislation provided a legal framework that consolidated the industry’s power and restricted competition from alternative medicines and treatments. This monopolistic control not only limited patient choices but also contributed to the rising costs of healthcare and prescription drugs.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…